Vera Therapeutics, Inc.
NGM: VERALive Quote
📈 ZcoreAI Score
Our AI model analyzes Vera Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VERA Z-Score →About Vera Therapeutics, Inc.
Healthcare
Biotechnology
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
📊 Fundamental Analysis
Vera Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -50.7%, which indicates that capital utilization is currently under pressure.
At a current price of $45.04, VERA currently sits at the 70th percentile of its 52-week range (Range: $18.76 - $56.05).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$3.23B
Trailing P/E
--
Forward P/E
-14.80
Beta (5Y)
1.17
52W High
$56.05
52W Low
$18.76
Avg Volume
1.18M
Day High
Day Low